BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 29982453)

  • 1. Human airway mucus alters susceptibility of Pseudomonas aeruginosa biofilms to tobramycin, but not colistin.
    Müller L; Murgia X; Siebenbürger L; Börger C; Schwarzkopf K; Sewald K; Häussler S; Braun A; Lehr CM; Hittinger M; Wronski S
    J Antimicrob Chemother; 2018 Oct; 73(10):2762-2769. PubMed ID: 29982453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PEGylation of Tobramycin Improves Mucus Penetration and Antimicrobial Activity against Pseudomonas aeruginosa Biofilms in Vitro.
    Bahamondez-Canas TF; Zhang H; Tewes F; Leal J; Smyth HDC
    Mol Pharm; 2018 Apr; 15(4):1643-1652. PubMed ID: 29514003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The MerR-like regulator BrlR impairs Pseudomonas aeruginosa biofilm tolerance to colistin by repressing PhoPQ.
    Chambers JR; Sauer K
    J Bacteriol; 2013 Oct; 195(20):4678-88. PubMed ID: 23935054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of oxygen limitation on the in vitro antimicrobial susceptibility of clinical isolates of Pseudomonas aeruginosa grown planktonically and as biofilms.
    Field TR; White A; Elborn JS; Tunney MM
    Eur J Clin Microbiol Infect Dis; 2005 Oct; 24(10):677-87. PubMed ID: 16249934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrobial efficacy against Pseudomonas aeruginosa biofilm formation in a three-dimensional lung epithelial model and the influence of fetal bovine serum.
    Crabbé A; Liu Y; Matthijs N; Rigole P; De La Fuente-Nùñez C; Davis R; Ledesma MA; Sarker S; Van Houdt R; Hancock RE; Coenye T; Nickerson CA
    Sci Rep; 2017 Mar; 7():43321. PubMed ID: 28256611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of Antibiotics against Pseudomonas aeruginosa in an
    Diaz Iglesias Y; Van Bambeke F
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015047
    [No Abstract]   [Full Text] [Related]  

  • 7. Increased bactericidal activity of colistin on Pseudomonas aeruginosa biofilms in anaerobic conditions.
    Kolpen M; Appeldorff CF; Brandt S; Mousavi N; Kragh KN; Aydogan S; Uppal HA; Bjarnsholt T; Ciofu O; Høiby N; Jensen PØ
    Pathog Dis; 2016 Feb; 74(1):ftv086. PubMed ID: 26458402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impairment of Pseudomonas aeruginosa Biofilm Resistance to Antibiotics by Combining the Drugs with a New Quorum-Sensing Inhibitor.
    Furiga A; Lajoie B; El Hage S; Baziard G; Roques C
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1676-86. PubMed ID: 26711774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breaking the Vicious Cycle of Antibiotic Killing and Regrowth of Biofilm-Residing
    Müsken M; Pawar V; Schwebs T; Bähre H; Felgner S; Weiss S; Häussler S
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30297365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pulmonary mucus surrogate for investigating antibiotic permeation and activity against Pseudomonas aeruginosa biofilms.
    Frisch S; Boese A; Huck B; Horstmann JC; Ho DK; Schwarzkopf K; Murgia X; Loretz B; de Souza Carvalho-Wodarz C; Lehr CM
    J Antimicrob Chemother; 2021 May; 76(6):1472-1479. PubMed ID: 33712824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does the mode of dispersion determine the properties of dispersed Pseudomonas aeruginosa biofilm cells?
    Wille J; Teirlinck E; Sass A; Van Nieuwerburgh F; Kaever V; Braeckmans K; Coenye T
    Int J Antimicrob Agents; 2020 Dec; 56(6):106194. PubMed ID: 33039591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polyester-based particles to overcome the obstacles of mucus and biofilms in the lung for tobramycin application under static and dynamic fluidic conditions.
    Ernst J; Klinger-Strobel M; Arnold K; Thamm J; Hartung A; Pletz MW; Makarewicz O; Fischer D
    Eur J Pharm Biopharm; 2018 Oct; 131():120-129. PubMed ID: 30063969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro evaluation of tobramycin and aztreonam versus Pseudomonas aeruginosa biofilms on cystic fibrosis-derived human airway epithelial cells.
    Yu Q; Griffin EF; Moreau-Marquis S; Schwartzman JD; Stanton BA; O'Toole GA
    J Antimicrob Chemother; 2012 Nov; 67(11):2673-81. PubMed ID: 22843834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibility of Pseudomonas aeruginosa Dispersed Cells to Antimicrobial Agents Is Dependent on the Dispersion Cue and Class of the Antimicrobial Agent Used.
    Chambers JR; Cherny KE; Sauer K
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28971863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa.
    Herrmann G; Yang L; Wu H; Song Z; Wang H; Høiby N; Ulrich M; Molin S; Riethmüller J; Döring G
    J Infect Dis; 2010 Nov; 202(10):1585-92. PubMed ID: 20942647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of Calgary and Microfluidic BioFlux Systems To Test the Activity of Fosfomycin and Tobramycin Alone and in Combination against Cystic Fibrosis Pseudomonas aeruginosa Biofilms.
    Díez-Aguilar M; Morosini MI; Köksal E; Oliver A; Ekkelenkamp M; Cantón R
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084746
    [No Abstract]   [Full Text] [Related]  

  • 17. Role of Viscoelasticity in Bacterial Killing by Antimicrobials in Differently Grown
    Rozenbaum RT; van der Mei HC; Woudstra W; de Jong ED; Busscher HJ; Sharma PK
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30745390
    [No Abstract]   [Full Text] [Related]  

  • 18. Asiatic acid and corosolic acid enhance the susceptibility of Pseudomonas aeruginosa biofilms to tobramycin.
    Garo E; Eldridge GR; Goering MG; DeLancey Pulcini E; Hamilton MA; Costerton JW; James GA
    Antimicrob Agents Chemother; 2007 May; 51(5):1813-7. PubMed ID: 17353241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tobramycin-Treated Pseudomonas aeruginosa PA14 Enhances Streptococcus constellatus 7155 Biofilm Formation in a Cystic Fibrosis Model System.
    Price KE; Naimie AA; Griffin EF; Bay C; O'Toole GA
    J Bacteriol; 2016 Jan; 198(2):237-47. PubMed ID: 26483523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of artificial sputum medium to test antibiotic efficacy against Pseudomonas aeruginosa in conditions more relevant to the cystic fibrosis lung.
    Kirchner S; Fothergill JL; Wright EA; James CE; Mowat E; Winstanley C
    J Vis Exp; 2012 Jun; (64):e3857. PubMed ID: 22711026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.